News
BGNE
166.95
+3.15%
5.10
Novartis, BeiGene tislelizumab/chemo improves survival of esophageal cancer patients in trial
BeiGene (NASDAQ:BGNE) and Novartis (NY...
Seekingalpha · 1d ago
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Benzinga · 1d ago
BeiGene Announced Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced new data from RATION...
Benzinga · 1d ago
BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3 Trial
MT Newswires · 1d ago
TAL Education, Mercury Fintech added to list of companies facing possible delisting by SEC
TAL Education Group (NYSE:TAL) and Mercury Fintech (NASDAQ:MFH) were added to a list of companies that face possible delisting from U.S. exchanges,  the Securities and Exchange Commission said on Friday.
Seekingalpha · 06/24 16:47
Insider Sell: Beigene
MT Newswires · 06/22 18:04
BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 06/22 12:10
BeiGene adds 12% as anti-PD-1 Inhibitor undergoes regulatory review in China
The ADRs of BeiGene (NASDAQ:BGNE) gained 12% in the pre-market Tuesday after the biotech announced that regulators in China have accepted a marketing application for drug combination involving its anti-PD-1 inhibitor,
Seekingalpha · 06/21 11:26
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 CAMBRIDGE, Mass.,
Benzinga · 06/21 11:15
BeiGene Says China Regulators Accept Supplemental Biologics License Application for Anti-PD-1 Inhibitor Tislelizumab
MT Newswires · 06/21 08:32
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 06/20 12:53
CMB International Starts BeiGene at Buy With $248.52 Price Target
MT Newswires · 06/17 09:26
BeiGene down 9% as FDA extends action date for Brukinsa supplemental approval
The U.S. FDA has extended the action date by three months to Jan. 20, 2023 Beigene's (NASDAQ:BGNE) supplemental New Drug Application for Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic
Seekingalpha · 06/13 15:40
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.
Benzinga · 06/13 13:04
BeiGene Announces BRUKINSA Is Approved In 50 Markets
BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar BRUKINSA has Previously Been Approved by
Benzinga · 06/13 11:35
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and acc...
Business Wire · 06/13 11:30
BeiGene Announces PDUFA Goal Date Extension For U.S. sNDA For BRUKINSA For The Treatment Of CLL/SLL
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,
Benzinga · 06/13 11:09
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and acc...
Business Wire · 06/13 11:00
BeiGene's Lymphoma Treatment Approved in Kuwait, Bahrain and Qatar
MT Newswires · 06/13 08:42
BeiGene Says US FDA Extends Fee Act for Supplementary New Drug Application for Brukinsa
MT Newswires · 06/13 07:29
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.